SEC Form 4 · accession 0001209191-18-021775
Outlook Therapeutics, Inc. · OTLK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joerg Windisch
Director
Period of report
Mar 23, 2018
Accepted (ET)
Mar 27, 2018 · 5:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001649989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.94 | Mar 23, 2018 | A | 25,000 | A | — | Mar 23, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F133.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on March 23, 2021, subject to the Reporting Person providing continued service through such date.